ArticleCancer medicine2021
Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 5 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Risk of developing a second primary cancer following a renal cell carcinoma: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- Risks of colorectal and extracolonic cancers following colorectal cancer: a systematic review and meta-analysis.JNCI cancer spectrum · 2025Pooled it
- Global incidence and prevalence of differentiated thyroid cancer in childhood: systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Risk of extracolonic second primary cancers following a primary colorectal cancer: a systematic review and meta-analysis.International journal of colorectal disease · 2022Pooled it
- Risk of second primary cancer among breast cancer patients: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Subsequent primary cancer risks for non-hereditary colorectal cancer survivors.EClinicalMedicine · 2026Article
- The effect of thyroid cancer on the survival of patients with digestive system tumors using SEER database.Scientific reports · 2024Article
- Analyzing Comorbidity Patterns in Patients With Thyroid Disease Using Large-Scale Electronic Medical Records: Network-Based Retrospective Observational Study.Interactive journal of medical research · 2024Article
- Article
- Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study.Current oncology (Toronto, Ont.) · 2022Article
- Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer.Biomedicines · 2022Article
- Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012.Cancer medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 19 institutions in 2 countries.
Funding
Abstract
backgroundThe number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC.
methodsWe analyzed two population-based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population-based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer.
resultsA total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12-1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI: 1.42-1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon-rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers.
conclusionsThe increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow-up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.